Genome-scale overexpression screening identifies product tolerance and efflux transport as key determinants of high-level L-tryptophan production in Escherichia coli.

L-tryptophan is a high-value aromatic amino acid widely used in the food, feed, and pharmaceutical industries. However, large-scale microbial production is constrained by insufficient precursor supply and limited strain tolerance to high product concentrations. In this study, modular metabolic engineering was first employed to enhance the availability of key precursors, including shikimate, serine, and glutamine, yielding strain TRPJ-13 with a 34.6% increase in L-tryptophan titer. To enhance strain tolerance, an indigo-based high-throughput reporter system was constructed and coupled with genome-scale overexpression library screening, leading to the identification of soxS as a tolerance-conferring target. Mechanistic analysis demonstrated that soxS upregulated lpxC to enhance lipopolysaccharide biosynthesis, thereby reinforcing membrane integrity and improving L-tryptophan tolerance. Combinatorial engineering of soxS and lpxC generated strain TRPJ-23, which increased L-tryptophan tolerance by 74.8% and L-tryptophan titer by 10.3%. Furthermore, YicL was identified as a novel transmembrane protein involved in L-tryptophan transport that effectively promoted L-tryptophan efflux, further increasing the titer by 9.0%. After fermentation optimization, strain TRPJ-28 produced 74.3 g/L L-tryptophan in a 5-L bioreactor, with a yield of 0.26 g/g and a productivity of 1.24 g/L/h. In a 1000-L pilot-scale bioreactor, TRPJ-28 reached a titer, yield, and productivity of 70.4 g/L, 0.25 g/g, and 1.17 g/L/h, respectively. This study provides new engineering insights for developing industrially promising L-tryptophan-producing strains.